S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ValiRxMedifocusPhysiomicsSalvaRx GroupImmunoCellular Therapeutics
SymbolLON:VALCVE:MFSLON:PYCLON:SALVNYSEAMERICAN:IMUC
Price Information
Current PriceGBX 0.14C$0.01GBX 2.65GBX 4.50$0.04
52 Week RangeN/AN/AN/AN/AN/A
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap£1.40 millionC$1.85 million£1.92 million£1.65 million$1.58 million
BetaN/AN/AN/AN/AN/A
Average Volume3,820,000133,0271,300,00049,570135,196
Sales & Book Value
Annual RevenueN/AC$2.59 million£783,101.00£64.50 millionN/A
Price / SalesN/A0.362.430.03N/A
CashflowGBX 0.09 per shareC$0.00 per shareGBX 0.61 per shareGBX 1.29 per shareN/A
Price / Cash1.4910.004.333.50N/A
Book ValueGBX 0.30 per shareC($0.06) per shareGBX 0.80 per shareGBX 15.40 per shareN/A
Price / BookN/A-0.080.030.00N/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSGBX (0.50)C($0.01)GBX (0.10)GBX 168.80N/A
Trailing P/E RatioN/AN/AN/A0.030.00
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio6.37%N/AN/A14.50%N/A
Current Ratio0.95%0.06%7.81%1.89%N/A
Quick Ratio0.95%0.05%7.31%1.89%N/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees12762N/A
Shares Outstanding1.02 billion184.98 million71.91 million36.70 million41.94 million
Next Earnings DateN/A11/12/2019 (Estimated)N/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
 ValiRxMedifocusPhysiomicsSalvaRx GroupImmunoCellular Therapeutics

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel